Applied Clinical Trials-11-01-2022

Ukraine invasion tests the resiliency and quick action of CROs and sponsors.

Experts gauge threat level for global trials amid staffing and funding issues.

Despite prevalent use in electronic devices, NRS and VAS are often implemented suboptimally.

Rare disease stakeholders speak out ahead of anticipated EU changes.

Industry experts reinforce not putting all eyes on the patient.

Click the title above for a link to open the Applied Clinical Trials November 2022 issue in an interactive PDF format.

Study shows more support is needed for clinical teams to ‘FAIRify’ their data.

Sheri Kuss, clinical quality group lead at Pfizer, discusses the new "culture of quality" in clinical trials.

CBER maps modernization plan to handle surge in research and applications.

Clinical trials must rely on internet surveys to incorporate the needs of industry and patients, but how can results be improved?

All stakeholders must play part in increasing implementation.